On the other hand, although it is speculated that bevacizumab may improve the immunosuppressive tumor microenvironment induced by CTNNB1 mutations, a report found no association between CTNNB1 mutations and objective response rate (ORR), DCR, or PFS in the context of Atezo + Bev treatment [63]. This evidence concerns the gene CTNNB1 and neoplasm.